The Drug-Induced Respiratory Disease Website and App

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XI.ba

Nonrespiratory AE of interest

Publications

Osman GA, Marra A, Iacono D, Giannelli V, Ricciardi S, Remotti D, Vecchione A, Ricci A, Palange P, Migliorino MR

Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.

Anti-cancer drugs. 2019;30(7):e0764

Grätz V, Langan EA, Neumann A, Zillikens D, Terheyden P

Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.

Melanoma research. 2019;29(5):516-521

Brumbaugh AD, Narurkar R, Parikh K, Fanucchi M, Frishman WH

Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.

Cardiology in review. 2019;27(2):97-107

Winer A, Bodor JN, Borghaei H

Identifying and managing the adverse effects of immune checkpoint blockade.

Journal of thoracic disease. 2018;10(Suppl 3):S480-S489